GUARD: Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community
Study Details
Study Description
Brief Summary
The Effects and Safety of Diabetic GUideline Algorithm Implementation in the Community (GUARD-Community) study is a 2-arm, cluster-randomized control trial to evaluate the effect and safety of guideline algorithm intervention performed by primary care physicians on cardiovascular and renal outcomes in elderly patients with high risk in community.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Diabetes is an important public health concern. Elderly diabetic patients are characterized by a long duration and complications, including chronic kidney disease and/or cardiovascular disease. In the past 30 years, the guidelines of CDS, EASD or ADA have been frequently updated. The latest guideline on pharmacological algorithm recommend that patients with cardiovascular, renal disease or very high/high CV risk patients should be treated with anti-diabetic drugs presenting target organ protection, including SGLT2i and GLP1RA. And the guideline recommend comprehensive control of the cardiovascular risk factors, such as hypertension and dyslipidemia.
This GUARD-Community study is a community based cluster-randomized controlled trial and will enroll 5600 or more participants in more than 120 clusters aged ≥ 65 years with T2DM and complicated with high/very high cardiovascular risk factors . The trial will evaluate the the effects and safety of intensive "Guideline" algorithm implementation on CVD and renal outcomes. The primary hypothesis is that guideline algorithm intervention implemented by primary care physicians will significantly reduce the risk of 4-point MACE (comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or hospitalization of heart failure) rates. In Phase 1 study, the control of blood sugar, blood pressure and lipids will be evaluated at 18 months after intervention. In Phase 2 study, the CVD and renal outcomes will be evaluated at 3 years. The study will last for 4 years.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Intensive guideline algorithm implementation SGLT2i or GLP-1RA recommended in priority in subjects at very high/high CV risk. The targets of intervention will be achieved at HbA1C <7%, blood pressure <130/80mmHg, LDL-c<1.8mmol/L at very high CV risk or <2.6mmol/L at high CV risk patients, antiplatelet as secondary prevention of ASCVD. |
Other: Intensive guideline algorithm implementation
Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C<7%, control blood pressure <130/80mmHg, LDL-c<1.8mmol/L at very high CV risk patients or <2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
|
Active Comparator: Conventional guideline algorithm implementation Treatment based on the current approaches implemented by local physicians(primary care physicians). Guideline based education and consults will be conducted to primary care physicians. |
Other: Conventional guideline algorithm implementation
The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
|
Outcome Measures
Primary Outcome Measures
- Primary Outcome of Phase 1: Comprehensive management effect of various cardiovascular risk factors in T2D,meeting control targets for a combination of A1c, BP, LDL-C. [18 months since randomization]
The proportion of participants with HbA1C<7.0%, blood pressure< 130/80 mm Hg,LDL-c<1.8mmol/L at very high CV risk or <2.6mmol/L at high CV risk.
- Primary Outcome of Phase 2: Composite of 3P MACE and hospitalization for heart failure. [3 years since randomization]
Time to occurrence of cardiovascular and cerebrovascular death, non-fatal myocardial infarction, non-fatal Stroke, hospitalization for heart failure.
Secondary Outcome Measures
- Secondary Outcome of Phase 1: Glycemic control rate [18 months since randomization]
The proportion of participants with tight glucose control, targeting HbA1c <7.0%
- Secondary Outcome of Phase 1: Mean HbA1C changes [18 months since randomization]
Mean HbA1C changes of participants
- Secondary Outcome of Phase 1: Mean systolic and diastolic pressure changes [18 months since randomization]
Mean systolic and diastolic pressure changes of participants
- Secondary Outcome of Phase 1: Mean LDL-c changes [18 months since randomization]
Mean LDL-c changes of participants
- Secondary Outcome of Phase 1: Adherence to guideline algorithm medication recommendation rate [18 months since randomization]
Use electronic medical recorded prescription and questionnaires to assess the proportion of participants who adhere to guideline recommended medication
- Secondary Outcome of Phase 2: Incident or worsening nephropathy [3 years since randomization]
Time to composite of incident macroalbuminuria (UACR >300 mg/g), a sustained decline in eGFR of 40% or more from baseline, or chronic renal replacement therapy, or renal death.
- Secondary Outcome of Phase 2: Cardiorenal composite endpoint [3 years since randomization]
Time to eGFR (MDRD formula) decrease ≥40%, renal replacement therapy, renal or cardiovascular death
- Secondary Outcome of Phase 2: 3P MACE [3 years since randomization]
Time to events occurence: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke
- Secondary Outcome of Phase 2: New onset of macroalbuminuria. [3 years since randomization]
Time to UACR>300mg/g
- Secondary Outcome of Phase 2: Changes of myocardial ischemia in electrocardiogram (ECG) [3 years since randomization]
Participants number of ECG ischemia demonstration occurence: ST-T segment depression more than 0.1mv in two adjacent leads of ECG compared with baseline, poor R wave progression.
- Secondary Outcome of Phase 2: New onset of albuminuria [3 years since randomization]
Time to UACR increase from <30mg/g to ≥30mg/g
- Secondary Outcome of Phase 2: Albuminuria progression [3 years since randomization]
Time to albuminuria progression: UACR increased by ≥30% and grade progression (ie, from normal to micro or macro, or from micro to macro)
- Secondary Outcome of Phase 2: Albuminuria regression [3 years since randomization]
Time to albuminuria regression: UACR grade regression(ie, from macro to micro or normal, or from micro to normal), and the UACR value decreases by more than or equal to 30%
- Secondary Outcome of Phase 2: Changes in the ratio of patients with normal or abnormal urine protein at the end of the study [3 years since randomization]
Rate change of normal or abnormal UACR. Normal means UACR<30mg/g. Abnormal means UACR≥30mg/g
- Secondary Outcome of Phase 2: Slope of eGFR decline [3 years since randomization]
Decrease of the eGFR over time
- Secondary Outcome of Phase 2: Retinopathy changes [3 years since randomization]
Occurrence or regression of retinopathy(ETDRS-DRSS)
- Secondary Outcome of Phase 2: Body weight change [3 years since randomization]
Absolute weight change and the percentage change of body weight
- Secondary Outcome of Phase 2: Changes of fatty liver prevalence [3 years since randomization]
Rate change of fatty liver.
- Secondary Outcome of Phase 2: Changes in beta-cell function [3 years since randomization]
Absolute change assessed by HOMA2-%β method
- Secondary Outcome of Phase 2: Changes in cognitive function [3 years since randomization]
Improvement or progression of cognitive function: The Mini-CogTM scale
- Secondary Outcome of Phase 2: The FRAIL scale [3 years since randomization]
Changes of the simple frailty questionnaire score
- Secondary Outcome of Phase 2: All-cause death [3 years since randomization]
Time to the death due to any cause
Other Outcome Measures
- Health Economics Indicators [3 years since randomization]
Cost-effectiveness analysis: quantification of Incremental Cost Ratio Life Cycle (ICER) and Quality Adjusted Years (QALYs)
- Changes in cardiovascular risk indicators [3 years since randomization]
Framingham score
- Serology and urine testing [3 years since randomization]
Biomarkers associated with diagnosis or prognosis: using "omics" screening.
- Genomics testing [3 years since randomization]
Gene polymorphism testing for drug response or prognosis: using genome-wide association study(GWAS) screening.
- The time rate of glycemic target range [3 years since randomization]
Continous glucose monitor detection
Eligibility Criteria
Criteria
Inclusion Criteria:
-
①Males or females aged 65 and above (≥65) receive treatment from the local community health service center;
-
②Diagnosed type 2 diabetes (ADA criteria):
-
- Typical symptoms of diabetes + random blood sugar ≥ 11.1mmol/L;
-
- Fasting blood glucose (FPG) ≥ 7.0mmol/L (fasting blood glucose is defined as no caloric intake within 8 hours);
-
- Oral glucose tolerance test 2h blood glucose (OGTT) ≥ 11.1mmol/L (2h after meal);
-
- have been treated with antidiabetic drugs;
-
Each blood sugar test must be repeated to confirm the diagnosis;
-
③Complicated with chronic kidney disease and/or very high/high risk of cardiovascular disease, meet any one of the following:
-
- ASCVD, including coronary heart disease, cerebral infarction, peripheral vascular disease;
-
- Or target organ damage (albuminuria, renal impairment with eGFR ≥ 30 ml/min/1.73m2, left ventricular hypertrophy or retinopathy);
-
- ≥ 3 major risk factors (age ≥ 65 years old, hypertension, dyslipidemia, smoking, obesity BMI ≥ 28kg/m2);
-
- Diabetes duration ≥ 10 years, with any one traditional cardiovascular risk factor such as advanced age, obesity, smoking, sedentary, family history of cardiovascular disease, hypertension, abnormal lipid metabolism.
Exclusion Criteria:
-
①Pregnant women or women planning to become pregnant;
-
②eGFR<30 mL/min/1.73m2 (MDRD formula);
-
③Patient cannot be followed up for 36 months (due to health condition or migration);
-
④Unwilling or unable to sign the informed consent;
-
⑤Type 1 diabetes;
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Shanghai Zhongshan Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124. doi: 10.2337/dc21-S009. Review.
- Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
- Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486. Review. Erratum in: Eur Heart J. 2020 Dec 1;41(45):4317.
- Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
- Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005 Jan;28(1):164-76. Review.
- Gu TW, Zhu DL. [Interpretation of treatment part of national guideline for the prevention and control of diabetes in primary care (2018)]. Zhonghua Nei Ke Za Zhi. 2019 Jul 1;58(7):538-540. doi: 10.3760/cma.j.issn.0578-1426.2019.07.011. Chinese.
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53. Erratum in: Lancet 1999 Aug 14;354(9178):602.
- Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. Epub 2016 Sep 15.
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
- Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021 Aug;44(8):1805-1815. doi: 10.2337/dc21-0076. Epub 2021 Jul 7.
- Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
- Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
- Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
- Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE-TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
- ZSE 20220401